Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | CASR | P41180 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9006023 | 0.84 | KMT2A (0.70) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL9006022 | 0.84 | KMT2A (0.70) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL6319902 | 0.81 | KMT2A (0.66) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| Oxalic Acid SCHEMBL6320367 | 0.79 | KMT2A (0.62) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| Oxalic Acid SCHEMBL6321308 | 0.79 | KMT2A (0.62) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL6321718 | 0.77 | KMT2A (0.60) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL11572631 | 0.76 | KMT2A (0.59) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL9628909 | 0.74 | ADRB2 (0.67) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| Oxalic Acid SCHEMBL11476332 | 0.73 | ADRB2 (0.65) | KMT2AADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL20049938 | 0.73 | CYP2D6 (0.69) | KMT2AADRB3ADRB1ADRB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORPORATION | 2003-11-20 | — | — | US | claimed |
| US-6906075-B2 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORP. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1107944-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012462-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | KMT2A 3075/4885ADRB3 2/4885ADRB1 1/4885 |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | MCHR1, MCHR2, MC1R | KMT2A 1318/4885ADRB3 140/4885ADRB1 205/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | KMT2A 3010/4885ADRB3 2/4885ADRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.